<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355379</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE34-ADAGE</org_study_id>
    <nct_id>NCT02355379</nct_id>
  </id_info>
  <brief_title>Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over</brief_title>
  <acronym>ADAGE</acronym>
  <official_title>Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France
      more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more.
      Adjuvant chemotherapy has demonstrated a benefit on disease-free survival and overall
      survival after a stage III colon cancer resection. Nevertheless adjuvant chemotherapy is
      poorly used in elderly patients. Prognostic improvement with chemotherapy based on 5FU is
      suggested by a post-hoc analysis of randomized prospective clinical trial. But elderly
      patients in this study were highly selected and patients older than 80 represented only 0.7%
      of the total population. Thus, there is still a concern about the benefit of adjuvant
      5FU-based chemotherapy in very elderly unselected patients.

      The recommended treatment for stage III adjuvant chemotherapy is a combination of
      fuoropyrimidine and oxaliplatin. Nevertheless oxaliplatin did not demonstrated survival
      advantage in elderly patients.

      Altogether there are still two matters of debate:

        -  First, is there a benefit of fluoropyrimidine-based adjuvant chemotherapy for unfit
           elderly patients?

        -  Second, is there a benefit of oxaliplatin-based adjuvant chemotherapy for fit elderly
           patients? The aim of this randomized phase III study is to evaluate the benefit for
           disease-free survival of adjuvant chemotherapy in elderly patient and which
           chemotherapy.

      The elderly patient population will be dichotomized into two groups according to physician's
      choice after a multidisciplinary evaluation involving a geriatrician, with two different
      randomization assignments. The patients with an expected life-expectancy below 4 years
      according Lee score are excluded of this study.

      Some biological tumour abnormalities are more frequently observed in elderly (i.e. mismatch
      repair deficiency), therefore an evaluation of specific biological prognostic factors is
      needed in elderly population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France
      more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more.
      Adjuvant chemotherapy has demonstrated a benefit on disease-free survival and overall
      survival after a stage III colon cancer resection. Nevertheless adjuvant chemotherapy is
      poorly used in elderly patients. Prognostic improvement with chemotherapy based on 5FU is
      suggested by a post-hoc analysis of randomized prospective clinical trial. But elderly
      patients in this study were highly selected and patients older than 80 represented only 0.7%
      of the total population. Thus, there is still a concern about the benefit of adjuvant
      5FU-based chemotherapy in very elderly unselected patients.

      The recommended treatment for stage III adjuvant chemotherapy is a combination of
      fuoropyrimidine and oxaliplatin. Nevertheless oxaliplatin did not demonstrated survival
      advantage in elderly patients.

      Altogether there are still two matters of debate:

        -  First, is there a benefit of fluoropyrimidine-based adjuvant chemotherapy for unfit
           elderly patients?

        -  Second, is there a benefit of oxaliplatin-based adjuvant chemotherapy for fit elderly
           patients? The aim of this randomized phase III study is to evaluate the benefit for
           disease-free survival of adjuvant chemotherapy in elderly patient and which
           chemotherapy.

      The elderly patient population will be dichotomized into two groups according to physician's
      choice after a multidisciplinary evaluation involving a geriatrician, with two different
      randomization assignments. The patients with an expected life-expectancy below 4 years
      according Lee score are excluded of this study.

      Some biological tumour abnormalities are more frequently observed in elderly (i.e. mismatch
      repair deficiency), therefore an evaluation of specific biological prognostic factors is
      needed in elderly population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 3-year disease-free survival</measure>
    <time_frame>3 years after last patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overal survival</measure>
    <time_frame>5 years after last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety: all observed toxicities, graded according to NCI-CTC v4 and the SAE</measure>
    <time_frame>3 years after last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of geriatric predictive factor</measure>
    <time_frame>3 years after last patient in</time_frame>
    <description>Exploratory analysis to search for geriatric prognostic factors for primary endpoint. Evolution of geriatric parametters during patients Follow-up</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">774</enrollment>
  <condition>Colonic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>GROUP1 -ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LV5FU2 or capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP1-ARMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX4 or XELOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP2- ARM C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP2-ARM D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LV5FU2 or capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2 or capectitabine</intervention_name>
    <arm_group_label>GROUP1 -ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX4 or XELOX</intervention_name>
    <arm_group_label>GROUP1-ARMB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>GROUP2- ARM C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2 or capecitabine</intervention_name>
    <arm_group_label>GROUP2-ARM D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 70 years

          -  Patient considered able to receive chemotherapy

          -  Lee score detailed faxed to CRGA

          -  Stage III colon adenocarcinoma

          -  R0 resection of the primary tumor

          -  Start of the potential adjuvant chemotherapy within 12 weeks after surgery

          -  No prior chemotherapy for colon cancer

          -  Geriatric Self-administered questionnaire completed faxed to CRGA

          -  Geriatric Questionnaire completed by the team faxed to CRGA

          -  Effective contraception for men patients throughout treatment and for at least 6
             months after discontinuation of oxaliplatin

          -  Consent signed

        Exclusion Criteria:

          -  Other progressive disease (cancer uncontrolled for less than 2 years)

          -  Rectal Cancer (located less than 15 cm from the anal verge endoscopy or
             sub-peritoneal)

          -  ANC &lt;2000 / mm3 for group 1 and ANC &lt;1500 / mm3 for group 2 and platelets &lt;100,000 /
             mm3 or hemoglobin &lt;9 g / dL

          -  Neuropathy for patients in group 1

          -  Known deficit of dihydropyrimidine dehydrogenase (DPD)

          -  Patients with severe hepatic insufficiency

          -  Any contrindication to the drugs used in the study

          -  Inability to submit to medical follow-up for geographical, social or psychological
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Aparicio, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>FFCD member</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Schneider</last_name>
    <phone>+33 3 80 39 34 83</phone>
    <email>martina.schneider@u-bourgogne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaique Cario</last_name>
    <phone>+33 3 80 39 34 86</phone>
    <email>jaique.cario_isat@u-bourgogne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CROMG</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela CAUCHOIS</last_name>
      <phone>05 53 69 12 00</phone>
    </contact>
    <investigator>
      <last_name>Adela CAUCHOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SÃ©vrine GUARNIERI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier CARLES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier BERNARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann BERGE</last_name>
      <email>berge@claude-bernard-albi.com</email>
    </contact>
    <investigator>
      <last_name>Yann BERGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe HOUYAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-HÃ©lÃ¨ne GASPARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amaury SYLVESTRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HOP PrivÃ©</name>
      <address>
        <city>Annemasse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oxana SHESTAEVA</last_name>
      <email>o.shestaeva@ramsaygds.fr</email>
    </contact>
    <investigator>
      <last_name>Oxana SHESTAEVA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital PrivÃ© Bonnettes</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno HUGUENIN</last_name>
      <email>drbhuguenin@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno HUGUENIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie BLANC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Avicenne</name>
      <address>
        <city>BOBIGNY cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas APARICIO, Pr</last_name>
      <phone>01 48 95 54 31</phone>
      <email>thomas.aparicio@avc.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mourad BENALLAOUA</last_name>
      <phone>01 48 95 54 31</phone>
      <email>thomas.aparicio@avc.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas APARICIO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence MARY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Cahors</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia LEVASSEUR</last_name>
      <email>nadia.levasseur@ch-cahors.fr</email>
    </contact>
    <investigator>
      <last_name>Nadia LEVASSEUR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Cherbourg en Cotentin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure KALUZINSKI</last_name>
      <email>l.kaluzinski@ch-cherbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Laure KALUZINSKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arm ELWESHI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Nicolas PINHO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Contamine sur Arve</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol ALLIOT</last_name>
      <email>calliot@ch-alpes-leman.fr</email>
    </contact>
    <investigator>
      <last_name>Carol ALLIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des CÃ¨dres</name>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle ROQUE</last_name>
      <email>isa.roque@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle ROQUE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain LEDIT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Flers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Emmanuel HENNERESSE</last_name>
      <email>pierre-emmanuel.henneresse@ch-flers.fr ; netpeh@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel HENNERESSE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent LION</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Gonesse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabri AHMED</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Le Coudray</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela TOSSEN</last_name>
      <email>gtossen@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Gabriela TOSSEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MichÃ¨le MANGOLD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne THIROT-BIDAULT</last_name>
      <email>anne.bidault@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne THIROT-BIDAULT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Radiologie</name>
      <address>
        <city>Macon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle POUCHARD</last_name>
      <email>rthmacon@orange.fr; iporlem@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle POUCHARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice LORCHEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas BARBET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Macon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny KAYAL</last_name>
      <email>fannykayal@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Fanny KAYAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal BERGER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie BELLECOSTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien TAIEB</last_name>
      <email>julien.taieb@egp.aphp.fr; jtaieb75@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Julien TAIEB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>CÃ©line LEPERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno LANDI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure POINTET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GÃ©raldine PERKINS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aziz ZAANAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Nicolas VAILLANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanne NETTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon PERNOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORIAT</last_name>
      <email>romain.coriat@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Romain CORIAT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion DHOOGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johann DREANIC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie TIGAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine BREZAULT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc GORNET</last_name>
      <email>jean-marc.gornet@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc GORNET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LOUVET</last_name>
      <email>christophe.louvet@imm.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mostefa BENNANMOUN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc MOLITOR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PitiÃ© SalpÃªtiÃ¨re</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DUBREUIL</last_name>
      <email>olivier.dubreuil@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier DUBREUIL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste BACHET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SolÃ¨ne DOAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Rodez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MOSSER</last_name>
      <email>l.mosser@ch-rodez.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent MOSSER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Saint Quentin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Innocenti DADAMESSI</last_name>
      <email>I.dadamessi@ch-stquentin.fr;dadamessi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Innocenti DADAMESSI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne THIROT-BIDAULT</last_name>
      <email>anne.bidault@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne THIROT-BIDAULT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant chemotherapy in colonic adenocarcinoma in elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

